Theratechnologies Inc. (NASDAQ:THTX) Q4 2023 Earnings Conference Call February 21, 2024 8:30 AM ET Company Participants Julie Schneiderman - Senior Director, Communications and Corporate Affairs Paul Levesque - President and Chief Executive Officer Philippe Dubuc - Senior Vice President and Chief Financial Officer John Leasure - Global Commercial Officer Christian Marsolais - Senior Vice President and Chief Medical Officer Conference Call Participants Carvey Leung - Cantor Fitzgerald Andre Uddin - Research ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Exhibit 99.1 Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance • Positive Adjusted EBITDA* for Q4 2023 more than doubles from Q3 2023 to $5 million (Net Loss of $2.8 million) leading to a significant turnaround for the full year versus 2022 • Record quarterly revenue of $23.5 million and annual revenue of $81.8 million • Updated Phase 1 trial investigating sudocetaxel zendusortide in advanced ovarian cancer reaches key milestone with e ...

财务数据和关键指标变化 - 第三季度营收为2090万美元,与去年同期持平,但较第二季度的1750万美元有所回升 [28] - 第三季度调整后EBITDA为220万美元,去年同期为-390万美元,第二季度为-610万美元 [36] - 第三季度净销售成本为500万美元,去年同期为530万美元 [31] - 第三季度研发费用同比下降36%,销售费用同比下降20%,管理费用同比下降12% [33][34][35] - 第三季度末现金及等价物为2290万美元 [38] 各条业务线数据和关键指标变化 - 第三季度EGRIFTA SV净销售额为1320万美元,同比增长2.3%,主要得益于售价上涨,但部分被政府回扣增加所抵消 [29] - 第三季度Trogarzo净销售额为770万美元,同比下降3.3%,主要由于停止在欧洲市场的销售,以及北美市场销量略有下降,但售价有所提高 [30] 公司战略和发展方向和行业竞争 - 公司专注于通过产品线扩展延长现有产品的生命周期,例如向FDA提交EGRIFTA F8制剂的上市申请 [15] - 公司致力于推进其主要抗癌药物sudocetaxel zendusortide的开发,计划在2024年报告1期临床试验的初步安全性和有效性数据 [15] - 公司正在寻求通过收购或合作来扩大其商业产品组合,重点关注HIV相关产品、HIV相邻领域以及小型代谢疾病产品 [75] 管理层对经营环境和未来前景的评论 - 管理层对2023年剩余时间和2024年的财务和运营计划充满信心,尽管面临一些挑战,但已从成功和挫折中吸取了教训 [13] - 管理层预计2023年全年收入将在8200万至8500万美元之间,较第二季度有所回升 [19] - 管理层认为,随着一些关键项目的完成,研发和运营费用将大幅减少,从而提高盈利能力 [17] - 管理层对与Marathon修改贷款契约感到满意,认为这反映了对其执行公司目标能力的信心 [16] 其他重要信息 - 公司使用调整后EBITDA作为衡量其运营绩效和财务状况的指标,认为该指标比IFRS或U.S. GAAP下的财务指标更能反映其日常运营情况 [7] - 公司已向FDA提交了Trogarzo IM制剂的上市申请,预计将在2023年第四季度获得批准 [22] - 公司正在推进其NASH资产的开发,并寻求研究合作伙伴 [25] 问答环节所有提问和回答 问题: EGRIFTA F8制剂的潜在市场影响 - 管理层认为,F8制剂将通过提高患者依从性来推动销售增长,但不会成为主要驱动因素 [43][45] 问题: 抗癌药物sudocetaxel zendusortide的研发支出预期 - 管理层预计,随着一些关键项目的完成,研发支出将减少,但不会影响其产生新处方的能力 [47][49][50] 问题: 2024年收入增长的主要驱动因素 - 管理层认为,EGRIFTA F8制剂将有助于推动2024年的销售增长,但主要驱动因素仍然是现有产品的持续增长 [56][58] 问题: Trogarzo IM制剂的给药方案 - 管理层表示,Trogarzo IM制剂需要每两周注射两次,每次2.3毫升,患者对该制剂的耐受性良好 [59][61] 问题: 第三季度产品销售的量价关系 - 管理层指出,第三季度产品销量持平,但价格有所上涨,部分被政府回扣增加所抵消 [66][67] 问题: 第四季度收入预期的驱动因素 - 管理层预计,第四季度收入增长将主要由销量驱动,没有计划在第四季度提价 [70][71] 问题: 公司对扩展商业产品组合的看法 - 管理层表示,正在寻求通过收购或合作来扩大其商业产品组合,重点关注HIV相关产品、HIV相邻领域以及小型代谢疾病产品 [75][76][78] 问题: 抗癌药物sudocetaxel zendusortide 1期临床试验的预期结果 - 管理层预计,到2024年年中,将有16名患者完成给药,并报告初步的安全性和有效性数据 [84][86]

Exhibit 99.1 Interim Consolidated Financial Statements (in thousands of United States dollars) THERATECHNOLOGIES INC. Three- and nine-month periods ended August 31, 2023 and 2022 (Unaudited) THERATECHNOLOGIES INC. Table of Contents (in thousands of United States dollars) (Unaudited) Page Interim Consolidated Statements of Financial Position 1 Interim Consolidated Statements of Comprehensive Loss 2 Interim Consolidated Statements of Changes in Equity 3 Interim Consolidated Statements of Cash Flows 4 Notes to ...

Theratechnologies Inc. (NASDAQ:THTX) Q2 2023 Earnings Conference Call July 12, 2023 8:30 AM ET Company Participants John Mullaly - Managing Director, United States, LifeSci Advisors Paul Levesque - President and CEO Philippe Dubuc - SVP and CFO Christian Marsolais - SVP and Chief Medical Officer John Leasure - Global Commercial Officer Conference Call Participants Louise Chen - Cantor Fitzgerald William Maughan - Canaccord Genuity Justin Walsh - JonesTrading Andre Uddin - Research Capital Endri Leno - Natio ...

Exhibit 99.1 Interim Consolidated Financial Statements (in thousands of United States dollars) THERATECHNOLOGIES INC. Three- and six-month periods ended May 31, 2023 and 2022 (Unaudited) THERATECHNOLOGIES INC. Table of Contents (in thousands of United States dollars) (Unaudited) Page Interim Consolidated Statements of Financial Position 1 Interim Consolidated Statements of Comprehensive Loss 2 Interim Consolidated Statements of Changes in Equity 3 Interim Consolidated Statements of Cash Flows 4 Notes to Int ...

Theratechnologies Inc. (NASDAQ:THTX) Q1 2023 Earnings Conference Call April 12, 2023 8:30 AM ET Company Participants Elif McDonald - Head of Investor Relations Paul Levesque - President and Chief Executive Officer John Leasure - Global Commercial Officer Philippe Dubuc - Chief Financial Officer Christian Marsolais - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Justin Walsh - JonesTrading Edward Nash - Canaccord Genuity Endri Leno - National Bank Operator Good morning, ladies and g ...

Exhibit 99.1 Interim Consolidated Financial Statements (In thousands of United States dollars) THERATECHNOLOGIES INC. Three-month periods ended February 28, 2023 and 2022 (Unaudited) THERATECHNOLOGIES INC. Table of Contents (In thousands of United States dollars) (Unaudited) Page Interim Consolidated Statements of Financial Position 1 Interim Consolidated Statements of Comprehensive Loss 2 Interim Consolidated Statements of Changes in Equity 3 Interim Consolidated Statements of Cash Flows 4 Notes to Interim ...

Theratechnologies Inc. (NASDAQ:THTX) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ET Company Participants Elif McDonald - Head of Investor Relations Paul Levesque - President and Chief Executive Officer Philippe Dubuc - Chief Financial Officer Christian Marsolais - Chief Medical Officer John Leasure - Global Commercial Officer Conference Call Participants Carvey Leung - Cantor Fitzgerald Andre Uddin - Research Capital Endri Leno - National Bank Operator Good morning, ladies and gentlemen and t ...